Physician profile
Peter Izzo
NPI 1063755700
$1,719.69
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $553 · 2021: $264 · 2022: $32.24 · 2024: $32.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $429.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $295.55 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $226.14 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.07 | 2019-2020 | |
| Novo Nordisk INC | $86.23 | 2019-2020 | |
| Amarin Pharma, INC. | $79.07 | 2019 | |
| Pfizer INC. | $76.54 | 2019-2020 | |
| Abbvie INC. | $60.22 | 2021 | |
| Glaxosmithkline, LLC. | $58.83 | 2019-2021 | |
| Allergan, INC. | $36.66 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $35.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.15 | 2019-2020 | |
| Eisai INC. | $22.56 | 2020 | |
| Amgen INC. | $19.09 | 2024 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2021 | |
| Genentech USA, INC. | $15.77 | 2019 | |
| Merck Sharp & Dohme LLC | $14.11 | 2019 | |
| Hikma Pharmaceuticals USA | $12.84 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.